<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707681</url>
  </required_header>
  <id_info>
    <org_study_id>MCRA06001A</org_study_id>
    <nct_id>NCT00707681</nct_id>
  </id_info>
  <brief_title>Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)</brief_title>
  <official_title>A Phase II Randomized, Controlled Study to Evaluate the Quality of Life, Survival and Therapeutic Benefits of MS-20 in Patient With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microbio Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Microbio Co Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients
      using European Organization for Research and Treatment of Cancer (EORTC) QLQ C-30
      questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, Overall survival rate, Change from baseline of the highest weight observed, Change from baseline of body weight</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MS-20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MS-20</intervention_name>
    <description>4 ml/vial</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4ml/vial</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects may be included in the study only if they meet all of the following criteria:

          1. Subject aged ≧ 20;

          2. Histologically documented, unresectable advanced HCC. For patients with difficulty in
             obtaining histological diagnosis, a &quot;clinical diagnosis&quot; of HCC is acceptable if all
             the following criteria are met:

               -  Chronic hepatitis B or C with evidence of liver cirrhosis;

               -  Presence of hepatic tumor(s) with image findings (sonography, CT scan) compatible
                  with HCC and no evidence of gastrointestinal tumors;

               -  Elevated serum α-fetoprotein level ≧ 400 ng/ml;

          3. Cancer of the Liver Italian Program (CLIP) score of 3-4;

          4. Liver transaminase ≦ 5 times upper normal limits (UNL);

          5. Patient fulfilling any of the follow conditions:

               -  Refuse to receive aggressive cancer therapy after explained to the subjects the
                  benefits and risks;

               -  Progressive malignant disease after previous radiotherapy, percutaneous ethanol
                  injection, radiofrequency ablation, transarterial embolization, transarterial
                  chemoembolization, systemic chemotherapy, immunotherapy, or any experimental
                  therapy, or unable to tolerate such therapy;

               -  No treatment of high priority is available;

          6. ECOG performance status of 0 - 2;

          7. Patients are willing and able to comply with study procedures and sign informed
             consent.

        Exclusion Criteria

        Subjects will be excluded from the study for any of the following reasons:

          1. Patient with history of HCC rupture;

          2. Medical condition requiring anticoagulant or anti-platelet drugs;

          3. Patients with brain metastases;

          4. Patient unable to receive oral medication;

          5. Patients with significant renal function impairment (creatinine&gt;1.5mg/dl), severe
             cardiac disease, e.g. angina pectoris, myocardial infarction, cardiac arrhythmia,
             congestive heart failure (New York Heart Association Functional Classification III and
             IV) or physical examination finding, or clinical laboratory finding giving reasonable
             suspicion of a disease or condition that might render the subject at high risk from
             treatment;

          6. Female subjects of childbearing potential who:

               -  are lactating; or

               -  have positive pregnancy test (urine) at V2;

          7. Active infection or on antiretroviral therapy for HIV disease;

          8. Patient with known hypersensitivity to any component of the study medication (soy bean
             or soy product).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng-Yuan Peng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Yeh, MS</last_name>
    <phone>886226558558</phone>
    <phone_ext>306</phone_ext>
    <email>davidyeh@microbio.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia Lo, MS</last_name>
    <phone>886226558558</phone>
    <phone_ext>307</phone_ext>
    <email>cynthia.lo@microbio.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>TaiChung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Yuan Peng, MD</last_name>
      <phone>886422052121</phone>
      <phone_ext>2264</phone_ext>
      <email>cypeng@www.cmuh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Cheng-Yuan Peng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2008</study_first_posted>
  <last_update_submitted>February 24, 2010</last_update_submitted>
  <last_update_submitted_qc>February 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. David Yeh, Director</name_title>
    <organization>MicroBio Co., Ltd.</organization>
  </responsible_party>
  <keyword>microbio, MS-20, Hepatoma, Advanced Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

